PH31099A - Methods of inhibiting dysfunctional uterine bleeding. - Google Patents

Methods of inhibiting dysfunctional uterine bleeding.

Info

Publication number
PH31099A
PH31099A PH49597A PH49597A PH31099A PH 31099 A PH31099 A PH 31099A PH 49597 A PH49597 A PH 49597A PH 49597 A PH49597 A PH 49597A PH 31099 A PH31099 A PH 31099A
Authority
PH
Philippines
Prior art keywords
uterine bleeding
dysfunctional uterine
methods
inhibiting
inhibiting dysfunctional
Prior art date
Application number
PH49597A
Inventor
Keohane Patrick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31099A publication Critical patent/PH31099A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A method of inhibiting dysfunctional uterine bleeding-comprising administering to a human in need thereof an effective amount of a compound having the formula <CHEM> wherein R<1> and R<3> are independently hydrogen, -CH3, <CHEM> wherein Ar is optionally substituted phenyl; R<2> is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
PH49597A 1993-12-21 1994-12-19 Methods of inhibiting dysfunctional uterine bleeding. PH31099A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,391 US5446053A (en) 1993-12-21 1993-12-21 Methods of inhibiting dysfunctional uterine bleeding

Publications (1)

Publication Number Publication Date
PH31099A true PH31099A (en) 1998-02-05

Family

ID=22623570

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49597A PH31099A (en) 1993-12-21 1994-12-19 Methods of inhibiting dysfunctional uterine bleeding.

Country Status (20)

Country Link
US (2) US5446053A (en)
EP (1) EP0659417B1 (en)
JP (1) JPH07215858A (en)
KR (1) KR950016726A (en)
CN (1) CN1109752A (en)
AT (1) ATE168887T1 (en)
AU (1) AU692490B2 (en)
CA (1) CA2138510A1 (en)
CZ (1) CZ321094A3 (en)
DE (1) DE69412049T2 (en)
DK (1) DK0659417T3 (en)
ES (1) ES2119094T3 (en)
GR (1) GR3027706T3 (en)
HU (1) HUT71469A (en)
IL (1) IL112037A (en)
NO (1) NO944930L (en)
NZ (1) NZ270167A (en)
PH (1) PH31099A (en)
RU (1) RU94044456A (en)
ZA (1) ZA9410080B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
KR20010080254A (en) * 1998-11-26 2001-08-22 야마구찌 다까시 Medicinal compositions for periodic administration
CA2372720C (en) 1999-05-04 2007-09-11 John Antony Kanis Androgen glycosides and androgenic activity thereof
IN191020B (en) 2000-03-28 2003-09-13 Dabur Res Foundation
WO2002094788A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
JP2004531559A (en) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー Tetrahydroquinoline derivatives for inhibiting diseases associated with estrogen deficiency or abnormal physiological response to endogenous estrogen
BR0312054A (en) * 2002-06-25 2005-10-18 Wyeth Corp Use of thiooxyindole derivatives in the preparation of medicaments useful in the treatment of hormone related conditions, and pharmaceutical kit
KR102295878B1 (en) 2021-06-16 2021-08-31 최경선 Self-use backbar

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives

Also Published As

Publication number Publication date
EP0659417A2 (en) 1995-06-28
EP0659417B1 (en) 1998-07-29
RU94044456A (en) 1996-10-10
JPH07215858A (en) 1995-08-15
US5446053A (en) 1995-08-29
ATE168887T1 (en) 1998-08-15
ZA9410080B (en) 1996-06-19
AU692490B2 (en) 1998-06-11
IL112037A (en) 1999-03-12
NO944930D0 (en) 1994-12-19
EP0659417A3 (en) 1995-09-06
NO944930L (en) 1995-06-22
IL112037A0 (en) 1995-03-15
CN1109752A (en) 1995-10-11
US5552416A (en) 1996-09-03
HU9403663D0 (en) 1995-02-28
KR950016726A (en) 1995-07-20
ES2119094T3 (en) 1998-10-01
DE69412049D1 (en) 1998-09-03
CZ321094A3 (en) 1995-08-16
CA2138510A1 (en) 1995-06-22
AU8156194A (en) 1995-06-29
GR3027706T3 (en) 1998-11-30
NZ270167A (en) 1997-08-22
DE69412049T2 (en) 1999-01-14
DK0659417T3 (en) 1998-12-07
HUT71469A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
IL111284A0 (en) Methods for inhibiting endometriosis
PH31099A (en) Methods of inhibiting dysfunctional uterine bleeding.
SG46324A1 (en) Methods of inhibiting uterine fibrosis
HU9403667D0 (en) Methods of inhibiting seborrhea and acne
ZA948027B (en) Methods for inhibiting angiogenesis and angiogenic diseases
AU8154194A (en) Method for increasing libido in post-menopausal women
PH31316A (en) Method for inhibiting cartilage degradation.
GR3036225T3 (en) Methods of inhibiting primary endometrial hyperplasia